Search

Your search keyword '"Reddy, Sanjay S."' showing total 79 results
Start Over Author "Reddy, Sanjay S."
79 results on '"Reddy, Sanjay S."'

51. The Chicago Consensus on peritoneal surface malignancies: Management of gastric metastases.

Author

Izquierdo, Francisco J., Schuitevoerder, Darryl, Plana, Alejandro, Eng, Oliver S., Sherman, Scott K., Badgwell, Brian, Johnston, Fabian M., Abdel‐Misih, Sherif, Blazer, Dan G., Dineen, Sean P., Luiza Gleisner, Ana, Grotz, Travis E., Hanna, Nader, Mogal, Harveshp, Möller, Mecker G., Reddy, Sanjay S., Senthil, Maheswari, Winer, Joshua H., Abbott, Daniel E., and Ahrendt, Steven A.

Subjects
CANCER, STOMACH cancer, METASTASIS, PALLIATIVE treatment, PATHOLOGISTS
Abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of gastric cancer specifically as it relates to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

52. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases.

Author

Chicago Consensus Working Group, Izquierdo, Francisco J., Schuitevoerder, Darryl, Plana, Alejandro, Eng, Oliver S., Sherman, Scott K., Badgwell, Brian, Johnston, Fabian M., Abdel-Misih, Sherif, Blazer III, Dan G., Dineen, Sean P., Gleisner, Ana Luiza, Grotz, Travis E., Hanna, Nader, Mogal, Harveshp, Möller, Mecker G., Reddy, Sanjay S., Senthil, Maheswari, Winer, Joshua H., and Abbott, Daniel E.

Abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of gastric cancer specifically as it relates to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

54. Neoadjuvant therapy in advanced melanoma.

Author

O'Brien, Shalana, primary, Dsouza, Jimson, additional, Shohat, Shirly, additional, Goel, Neha, additional, Reddy, Sanjay S., additional, Olszanski, Anthony J., additional, Movva, Sujana, additional, Wu, Hong, additional, Yu, Jian Qin, additional, Lango, Miriam, additional, and Farma, Jeffrey M., additional

Published
2018
Full Text
View/download PDF

57. Mo1163 A Multicenter Study Evaluating Risk Factors of Lymph Node Metastasis in Early Gastric Cancer in the United States

Author

Brewer Gutierrez, Olaya Isabella, primary, Choi, Alyssa Y., additional, Draganov, Peter V., additional, Khanna, Lauren, additional, Sethi, Amrita, additional, Bartel, Michael J., additional, Abe, Seiichiro, additional, Ali, Rabia, additional, Park, Kenneth, additional, Melis, Marcovalerio, additional, Newman, Elliot, additional, Hatzaras, Ioannis, additional, Hwang, Joo Ha, additional, Reddy, Sanjay S., additional, Farma, Jeffrey M., additional, Liu, Xiuli, additional, Schlachterman, Alexander, additional, Kresak, Jesse, additional, Gaddam, Srinivas, additional, Hanada, Yuri, additional, Montgomery, Elizabeth, additional, Johnston, Fabian, additional, Duncan, Mark, additional, Canto, Marcia I., additional, Ahuja, Nita, additional, Lennon, Anne Marie, additional, and Ngamruengphong, Saowonee, additional

Published
2017
Full Text
View/download PDF

67. Incidence of ALK, cKIT, cMET, EGFR, PD1/PD-L1, and JAK3 alterations in 170 malignant pleural mesotheliomas (MPM) and 102 peritoneal mesotheliomas.

Author

Arguello, David, primary, El-Deiry, Wafik S., additional, Zhou, Lanlan, additional, Reddy, Sanjay S., additional, Scott, Walter Joseph, additional, Abass, Abass E., additional, Kaiser, Larry R., additional, Hallman, Mark A, additional, Sawhney, Rishi, additional, Jeong, Woondong, additional, Kim, Edward S., additional, Liu, Stephen V., additional, Ma, Patrick C., additional, Gatalica, Zoran, additional, Reddy, Sandeep K., additional, Borghaei, Hossein, additional, and Testa, Joseph R., additional

Published
2016
Full Text
View/download PDF

79. Discrepancies in survival after conversion to open in minimally invasive pancreatoduodenectomy.

Author

Villano AM, Ruth K, Castellanos J, Farma JM, and Reddy SS

Subjects
Humans, Pancreaticoduodenectomy methods, Pancreas surgery, Hospitals, Databases, Factual, Postoperative Complications epidemiology, Postoperative Complications surgery, Retrospective Studies, Minimally Invasive Surgical Procedures methods, Neoplasms surgery, Laparoscopy, Pancreatic Neoplasms pathology
Abstract

Background: The extent by which conversion to open (CTO) during minimally invasive procedures for pancreatic cancer impact survival outcomes is not fully understood., Methods: The 2010-2017 National Cancer Database identified 12,424 non-metastatic patients who underwent pancreatoduodenectomy for ductal adenocarcinoma. Patients were stratified into three cohorts: open (OPD), completed MIPD (cMIPD), and CTO. Subgroups were dichotomized by hospital MIPD volume., Results: Across the study period, 80.6% of patients underwent OPD, 19.4% MIPD, and 24% were CTO. Median overall survival was worse after CTO (21.8 months) than for OPD (23.6 months) or cMIPD (25.2 months) (p < 0.001). Although this effect persisted for <10 MIPD/year, CTO did comparably to OPD at hospitals performing ≥10MIPD/year (CTO = 26.8 months, OPD = 27.9 months; p = 0.128). Ninety-day mortality after CTO was worse at ≤ 10 MIPD/year hospitals (9.3% vs. 2.6%)., Conclusions: Short and long-term survival is impacted by CTO after MIPD, especially at lower surgical volumes, stressing careful adoption while ascending the learning curve., Competing Interests: Declaration of competing interest None., (Copyright © 2022 Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results